Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/31487
Title: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Authors: 
Keywords: 
Issue Date: Sep-2017
Citation: Breast Cancer Res. Treat..2017 Sep;(165)2:329-341
Abstract: Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels.
PMID: 28612225
URI: https://hdl.handle.net/20.500.12530/31487
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5543189.pdf1 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.